This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

William B. White, MD; Susan E. Halley, MD

Arch Intern Med. 1989;149(4):870-874.

Abstract
• We studied the renal effects of intravenous administration of fenoldopam mesylate, a dopamine-1 agonist, vs sodium nitroprusside following acute reduction of blood pressure (BP) in 11 patients with severe hypertension (supine BP, 168/124 to 252/135 mm Hg). Following randomization (open-label), timed urinary and plasma samples for clearance of urea and creatinine and excretion of sodium, potassium, and calcium were obtained as well as plasma renin activity for a two-hour collection prior to infusion, during a two-hour period of BP control (supine diastolic BP, 95 to 110 mm Hg), and following two hours off the drugs. Mean arterial pressure was lowered similarly with the two drugs (–22% on fenoldopam vs –20% on nitroprusside; P=NS), and neither plasma renin activity nor plasma aldosterone concentration were changed by either drug. However, patients receiving fenoldopam had significant increases in urinary flow and excretion of sodium, potassium, and calcium, whereas patients receiving nitroprusside had no changes in these parameters. Patients receiving fenoldopam had a net fluid balance of –334 mL from the end of baseline to the end of the treatment period, while the nitroprusside group had a positive balance of 382 mL. Thus, these findings show that acute BP reduction with fenoldopam is associated with both a diuresis and natriuresis in severely hypertensive patients while lowering BP with nitroprusside does not predictably alter renal function and causes a moderate expansion in volume.

(Arch Intern Med 1989;149:870-874)

Author Affiliations
From the Section of Hypertension and Vascular Diseases, University of Connecticut School of Medicine, Farmington. Dr White is currently with the Section of Cardiology, Medical Department A, University of Bergen (Norway) School of Medicine.

Footnotes
Accepted for publication Oct 26, 1988.

Presented at the third annual meeting of the American Society of Hypertension, New York, June 23, 1988.

Reprint requests to Section of Hypertension (Room Amo 39), University of Connecticut Health Center, Farmington, CT 06032 (Dr White).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Hypertensive Crises: Challenges and Management
Marik and Varon
Chest 2007;131:1949-1962.
ABSTRACT | FULL TEXT  

A Comparison of Fenoldopam with Dopamine and Sodium Nitroprusside in Patients Undergoing Cross-Clamping of the Abdominal Aorta
Oliver et al.
Anesth. Analg. 2006;103:833-840.
ABSTRACT | FULL TEXT  

To Dilate or Not To Dilate
Rocca and Pompei
Anesth. Analg. 2005;101:1242-1242.
FULL TEXT  

Renoprotective Action of Fenoldopam in High-Risk Patients Undergoing Cardiac Surgery: A Prospective, Double-Blind, Randomized Clinical Trial
Bove et al.
Circulation 2005;111:3230-3235.
ABSTRACT | FULL TEXT  

Fenoldopam Prophylaxis of Postoperative Acute Renal Failure in High-Risk Cardiac Surgery Patients
Ranucci et al.
Ann. Thorac. Surg. 2004;78:1332-1337.
ABSTRACT | FULL TEXT  

Fenoldopam Versus Nitroprusside for the Treatment of Hypertensive Emergency
Devlin et al.
The Annals of Pharmacotherapy 2004;38:755-759.
ABSTRACT | FULL TEXT  

The Diagnosis and Management of Hypertensive Crises
Varon and Marik
Chest 2000;118:214-227.
ABSTRACT | FULL TEXT